InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy OfficerGlobeNewsWire • 09/17/20
InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced PneumoniaGlobeNewsWire • 09/14/20
Are Options Traders Betting on a Big Move in InflaRx (IFRX) Stock?Zacks Investment Research • 07/24/20
InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced PneumoniaGlobeNewsWire • 07/21/20
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19GlobeNewsWire • 06/17/20
InflaRx (IFRX): Strong Industry, Solid Earnings Estimate RevisionsZacks Investment Research • 06/11/20
InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a TechnologyGlobeNewsWire • 03/31/20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma GangraenosumGlobeNewsWire • 02/26/20
InflaRx Tanks 91.79% As IFX-1 Phase II Trial Flops, Provides Bargain Buy For Competitor ChemoCentryxSeeking Alpha • 06/08/19
InflaRx Shares Slammed As Skin Inflammation Drug Flunks Midstage Trial; ChemoCentryx Moves In SympathyBenzinga • 06/05/19